A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML
Theodoros Karantanos(The University of Texas MD Anderson Cancer Center), Suman Paul(Johns Hopkins University), Richard J. Jones(Sidney Kimmel Cancer Center), Brandy Perkins(Johns Hopkins University), Teodora Supeanu(Johns Hopkins University), Ivana Gojo(Johns Hopkins University), Bogdan C. Paun(Johns Hopkins University), Theodora Chatzilygeroudi(Johns Hopkins University), Linda Resar(Johns Hopkins Medicine), Tushar D. Nichakawade(Howard Hughes Medical Institute), Gabriel Ghiaur(Johns Hopkins University), J. David Peske(University of Virginia), Zanshé Thompson(University of South Carolina), Yoon‐Kyo An(Johns Hopkins University), Nour Sabiha Naji(Johns Hopkins University), Taha Ahmedna(Howard Hughes Medical Institute), Mark J. Levis(Johns Hopkins University), Styliani Karanika(The University of Texas MD Anderson Cancer Center), Li Luo(Johns Hopkins University), Xinghan Zeng(Johns Hopkins University), Bum Seok Lee(Johns Hopkins University), Evangeline Watson(Howard Hughes Medical Institute), Melanie Klausner(Johns Hopkins University), Amy E. DeZern(Johns Hopkins University)
Cited by 0
Related Papers
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k
Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches
|Oncogene|2013|879
Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations
|Nature|2015|501
Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation
|Cancer Chemotherapy and Pharmacology|1989|406